4th Cleaning Validation Conference

Event Details
Senior QA Associate CAPA Lead
Eli Lilly
Principal Toxicologist
SafeBridge Europe
Head Validation
Novartis AG
ERT, PhD, MSCTox
Aesti
Senior CQV CAPEX Project Engineer
LONZA
Senior GMP Consultant
Passion4Quality
Independent Pharmaceutical Consultant
Borer Chemie AG
EMEA Training Manager & Critical Environments Specialist
DuPont de Nemours
Head of Global Quality Assurance Chemical APIs
Bayer AG
Principal Process Validation Consultant
ValSource Inc.
Technical Service Manager
STERIS Life Sciences
Business Development/Chair – ASTM E55.11 Process Design
Rattiinox
Managing Toxicologist
SafeBridge Europe

The 4th Cleaning Validation Conference, taking place on 24–25 March 2027 in Barcelona, Spain. Over two days, leading pharmaceutical manufacturers, regulators, and industry experts will explore the latest advances in science- and risk-based cleaning validation throughout the product lifecycle. The program will cover regulatory expectations, Health-Based Exposure Limits (HBELs), Contamination Control Strategy (CCS), equipment cleanability, analytical technologies, digitalization, and practical implementation of lifecycle cleaning validation. Through real-world case studies and interactive discussions, participants will gain practical solutions to strengthen compliance, improve operational efficiency, and prepare for future regulatory challenges.

Subject 1 – Strategy, Science & Regulatory Expectations

  • Regulatory Updates, Inspection Trends & Recent Findings in Cleaning Validation
  • Risk-Based Cleaning Validation & Quality Risk Management Throughout the Lifecycle
  • HBEL/PDE in Practice: From Toxicological Assessment to Cleaning Limits
  • Advanced HBEL Strategies for ADCs, Oligonucleotides, Biologics & New Modalities
  • Cleaning Validation as a Key Element of Contamination Control Strategy (CCS)
  • Scientific Worst-Case Product & Equipment Selection
  • Equipment Design, Cleanability & Hygienic Engineering
  • AI, Digitalization & Data-Driven Cleaning Validation

    Subject 2 – Practical Implementation & Continuous Improvement

  • Cleaning Process Development, Optimization & Validation
  • Risk-Based Sampling: Swab, Rinse, Visual Inspection & Analytical Methods
  • Visual Inspection: Establishing and Defending Scientifically Justified Limits
  • Continued Cleaning Verification, Lifecycle Monitoring & Revalidation
  • Deviations, Investigations & CAPA: When Cleaning Validation Fails
  • Cleaning Highly Potent Compounds in Shared and Multi-Product Facilities
  • Defending Cleaning Limits and Validation Strategies During Inspections
  • Regulatory Case Studies, Inspection Findings & Lessons Learned

    Who Should Join

    Cleaning Validation & Lifecycle Professionals
    Professionals responsible for the development, execution, maintenance and continuous improvement of Cleaning Validation programs across pharmaceutical, biotechnology, sterile manufacturing, ATMP and vaccine production facilities.

    Quality, Validation & Regulatory Experts
    Professionals from QA, QC, Validation, Regulatory Affairs, Compliance and Analytical Development responsible for regulatory alignment, inspection readiness, analytical strategies and robust Cleaning Validation programs.

    MS&T, Engineering & Technical Specialists
    Experts from MS&T, Engineering, Technical Services, process development and automation, as well as equipment manufacturers, responsible for equipment cleanability, process optimization, technology transfer and lifecycle performance.

    CCS, Microbiology, Toxicology & QRM Professionals
    Specialists involved in Contamination Control Strategy (CCS), Quality Risk Management (QRM), Microbiology, Environmental Monitoring, Industrial Hygiene, Occupational Toxicology and HBEL/PDE assessments.

    Manufacturing, Operations & Site Leaders
    Production managers, site leaders, facility and plant management professionals responsible for manufacturing systems, operational controls, cleaning performance, contamination prevention and product quality.

    Project Leaders, CMO/CDMO & Consultants
    Project managers, CMO/CDMO representatives, consultants and decision-makers seeking practical solutions, regulatory insights and innovative technologies to improve Cleaning Validation efficiency, compliance and inspection readiness.

  • Current regulatory expectations for Cleaning Validation and cross-contamination prevention
  • Regulatory case studies highlighting key challenges and compliance gaps
  • Recent inspection findings related to Cleaning Validation and cross-contamination risks
  • Lessons learned from inspections and their impact on validation strategies
  • Andreas Schreiner Practical approaches to inspection readiness and effective cross-contamination control
  • Modality-Specific Toxicological Nuances: Evaluating HBEL derivation for non-traditional
    platforms (oligonucleotides, ADCs, lipid nanoparticles), where classic animal carcinogenicity
    or long-term safety data are limited

  • Route-to-Route Extrapolation Strategies: Scientifically adjusting oral/IV PDE baseline values
    to respiratory or ocular routes while accounting for systemic bioavailability, local tissue
    irritation, and portal-of-entry effects

  • Defending Limits Under Audit Scrutiny: Key regulatory expectations (EMA, FDA) and
    common pitfalls when justifying safety factors, bio-inactivation assumptions, and non-linear
    toxicological endpoints to inspectors

  • Introduction to new modalities: ADCs, protein degraders, bispecific antibodies, etc.
  • PDE/HBEL calculation strategies for new and complex modalities
  • Approaches to addressing limited or evolving toxicological data
  • Equipment CIP-Cleanability Hazard Knowledge Management (ICH Q9(R1) and ICH Q10)
  • Identification and Grading of Equipment CIP-Cleanability Hazards on Supplier P&IDs
  • Supplier Selection and Challenge: Risk Analysis Supported by Data, Accessibility of Hard-to-
    Clean Areas, and Validation Planning

  • Cleanability Checks and Testing at FAT (Factory Acceptance Testing) – Before You Pay!
  • Cleaning Ownership (from Conception to Grave) and Cleaning Governance
  • Leadership Commitment – Recent FDA Warning Letters Regarding the Lack of “Resources
    and Authority” in Quality Departments

  • Establishing acceptance limits for formulated cleaning agents based on PDE (Permitted Daily
    Exposure)

  • Applying the traditional MACO (Maximum Allowable Carryover) approach and practical
    calculation methods

  • Selecting suitable analytical methods: available options, advantages, and limitations
  • Interpreting typical analytical results and addressing common challenges
  • Recent Regulatory Warning Letters and Inspection Findings Related to Shared Manufacturing
    Facilities

  • Developing a Risk-Based Contamination Control Strategy (CCS)
  • Technical Controls for Preventing Cross-Contamination in Shared Facilities
  • Organizational and Procedural Measures for Managing High-Hazard Products
  • Demonstrating Effective Containment and Preventing Cross-Contamination of Non-
    Hazardous Products

  • Practical Case Study: Justifying the Manufacture of Steroid Products Using Shared Equipment
  • The role of cleanroom garments within Cleaning Validation and the Contamination Control
    Strategy (CCS)

  • Selection criteria and qualification expectations for cleanroom garment systems
  • Contamination risks throughout the garment lifecycle, including use, handling, laundering,
    storage, and end-of-life decisions

  • Garment monitoring routines and how they support GMP Annex 1 compliance and a validated
    state of control

  • Cleaning Ownership as a lifecycle concept – defining clear responsibility across Engineering,
    Manufacturing, Validation, Quality, MSAT, and equipment suppliers

  • Identifying ownership gaps where critical cleaning decisions are delayed, fragmented, or left
    without clear accountability

  • Why Cleaning Validation teams inherit problems originating earlier in equipment design,
    process development, and operational decisions

  • Building earlier cross-functional collaboration to establish robust, practical, and scientifically
    justified cleaning processes

  • Strengthening cross-contamination control and inspection readiness through clear
    ownership throughout the equipment and process lifecycle

  • HBEL/PDE in Practice: Scientific Justification vs. Regulatory Expectations
  • Cleaning Validation for New Modalities and Highly Potent Products
  • Route-to-Route Extrapolation: Where Does the Science End and Uncertainty Begin?
  • Defending Cleaning Validation Strategies During Regulatory Inspections
  • Recent FDA Inspection Findings, Questions & Observations
  • Defining Clean Hold Time (CHT) and Dirty Hold Time (DHT)
  • Key Objectives of Clean and Dirty Hold Time Studies
  • Regulatory Expectations for Establishing and Validating Hold Times
  • Practical Case Studies: Successfully Designing and Implementing Hold Time Studies
  • Regulatory Landscape and Compliance
  • Toxicological Classification and Risk Mitigation
  • Advanced Processing and Handling of HPAPIs
  • Lifecycle-Based Cleaning Evaluation
  • Ask the questions that influence design: Identify which product and process information
    affects equipment selection, materials, cleaning methods, drainage, inspection, and sampling
    access

  • Make uncertainty part of the engineering concept: Document assumptions and assess where
    adaptable equipment, additional studies, or future design decisions are needed

  • Assess compatibility within a multiproduct facility: Consider whether existing equipment and
    cleaning systems can accommodate the new product and how its introduction could affect
    other products and manufacturing schedules

  • Connect the proposal to technical feasibility: Involve engineering and cleaning specialists
    early to ensure that scope, costs, and timelines reflect the available evidence and the work still
    required

  • Strengthen client–CDMO collaboration: Agree on responsibilities for providing data, testing
    cleanability, and reviewing design decisions as product knowledge develops, with clear
    checkpoints before equipment procurement and design freeze

  • 2 days access
    Original price was: €1,199.Current price is: €699.
  • Full Access
  • Post-event documentation
  • Certificate of attendance
  • Conference Recordings
  • Group booking
    Original price was: €2,499.Current price is: €1,499.
  • 3 or More Delegates
  • Full Access
  • Certificate of Attendance
  • Post-Event Documentation
  • Conference Recordings
  • 4th Cleaning Validation Conference
    Name
    Name
    First
    Last
    Agree
    Event Details
    Sponsors